Tìm theo
Eletriptan
Các tên gọi khác (1) :
  • Eletriptanum
serotonin antagonists, serotonin receptor agonists, anti migraine agents
Thuốc Gốc
Small Molecule
CAS: 143322-58-1
ATC: N02CC06
ĐG : Chunghwa Chemical Synthesis and Biotech Co. Ltd. , http://www.ccsb.com.tw
CTHH: C22H26N2O2S
PTK: 382.519
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. [Wikipedia]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C22H26N2O2S
Phân tử khối
382.519
Monoisotopic mass
382.171498776
InChI
InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
InChI Key
InChIKey=PWVXXGRKLHYWKM-LJQANCHMSA-N
IUPAC Name
5-[2-(benzenesulfonyl)ethyl]-3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-1H-indole
Traditional IUPAC Name
eletriptan
SMILES
CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
Độ hòa tan
Readily soluble as hydrobromide formulation
logP
3.9
logS
-5.5
pKa (strongest acidic)
17.11
pKa (Strongest Basic)
8.37
PSA
53.17 Å2
Refractivity
110.94 m3·mol-1
Polarizability
42.99 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
3
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
4
Bioavailability
1
Rule of Five
true
Ghose Filter
true
MDDR-Like Rule
true
Dược Lực Học : Eletriptan is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, eletriptan has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Eletriptan has also been shown to inhibit trigeminal nerve activity in the rat.
Cơ Chế Tác Dụng : Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. [Wikipedia] Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. Eletriptan has no significant affinity or pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. Two theories have been proposed to explain the efficacy of 5-HT receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
Dược Động Học :
▧ Absorption :
Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%.
▧ Volume of Distribution :
* 138 L
▧ Protein binding :
Plasma protein binding is moderate and approximately 85%.
▧ Metabolism :
In vitro studies indicate that eletriptan is primarily metabolized by cytochrome P-450 enzyme CYP3A4. The N-demethylated metabolite of eletriptan is the only known active metabolite.
▧ Half Life :
The terminal elimination half-life of eletriptan is approximately 4 hours.
▧ Clearance :
* Renal cl=3.9 L/h
Độc Tính : Based on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.
Chỉ Định : For the acute treatment of migraine with or without aura in adults.
Tương Tác Thuốc :
  • Citalopram Increased risk of CNS adverse effects
  • Clarithromycin The macrolide, clarithromycin, may increase the effect and toxicity of eletriptan.
  • Desvenlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Dihydroergotamine Possible severe and prolonged vasoconstriction
  • Ergonovine Possible severe and prolonged vasoconstriction
  • Ergotamine Possible severe and prolonged vasoconstriction
  • Erythromycin The macrolide, erythromycin, may increase the effect and toxicity of eletriptan.
  • Escitalopram Increased risk of CNS adverse effects
  • Fluoxetine Increased risk of CNS adverse effects
  • Fluvoxamine Increased risk of CNS adverse effects
  • Itraconazole This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
  • Ketoconazole This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
  • Methylergometrine Possible severe and prolonged vasoconstriction
  • Methysergide Possible severe and prolonged vasoconstriction
  • Nefazodone Increased risk of CNS adverse effects
  • Nelfinavir The protease inhibitor, nelfinavir, may increase the effect and toxicity of eletriptan.
  • Paroxetine Increased risk of CNS adverse effects
  • Ritonavir The protease inhibitor, ritonavir, may increase the effect and toxicity of eletriptan.
  • Sertraline Increased risk of CNS adverse effects
  • Telithromycin Telithromycin may reduce clearance of Eletriptan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eletriptan if Telithromycin is initiated, discontinued or dose changed.
  • Tramadol Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Tranylcypromine Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
  • Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Trimipramine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Troleandomycin The macrolide, troleandomycin, may increase the effect and toxicity of eletriptan.
  • Venlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eletriptan by decreasing its metabolism. Consider avoiding administration of the two agents within 72 hours of each other. Monitor for changes in the therapeutic and adverse effects of eletriptan if voriconazole is initiated, discontinued or dose changed.
  • Zolmitriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and eletriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Relpax
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00216
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=77993
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506380
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D01973
ChemSpider
http://www.chemspider.com/Chemical-Structure.70379.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0049-2340-05
PharmGKB
http://www.pharmgkb.org/drug/PA134687947
Wikipedia
http://en.wikipedia.org/wiki/Eletriptan
RxList
http://www.rxlist.com/cgi/generic3/relpax.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/rel1663.shtml
Drugs.com
http://www.drugs.com/cdi/eletriptan.html
... loading
... loading